Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 4/20 | 0.59 |
| ▸ | CTSK | P43235 | 3/20 | 0.59 |
| ▸ | CTSB | P07858 | 2/20 | 0.59 |
| ▸ | CTSL | P07711 | 1/20 | 0.59 |
| ▸ | ACE | P12821 | 1/20 | 0.57 |
| ▸ | GNPAT | O15228 | 1/20 | 0.56 |
| ▸ | REN | P00797 | 5/20 | 0.56 |
| ▸ | AKT1 | P31749 | 1/20 | 0.53 |
| ▸ | ECE1 | P42892 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3789929 | 1.00 | CTSS (0.59) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL29839818 | 1.00 | CTSS (0.59) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL30402156 | 0.96 | CTSS (0.55) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL9495487 | 0.96 | CTSS (0.55) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL11038198 | 0.96 | ACE (0.60) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL11038196 | 0.96 | ACE (0.60) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL30977093 | 0.94 | REN (0.65) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL28668847 | 0.94 | REN (0.65) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL30424553 | 0.94 | REN (0.65) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL28668852 | 0.94 | REN (0.65) | CTSSCTSKCTSBCTSLACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705045-B2 | compounds comprising a specifier linked to two or more of the same or different leaving groups via a self-eliminating multiple release spacer or spacer system, which compounds upon a single activation step, in particular removal or transformation of the specifier, release two or more leaving groups | SYNTARGA, B.V. (NL) | 2010-04-27 | — | — | US | claimed |
| EP-1370298-B1 | ELONGATED AND MULTIPLE SPACERS IN ACTIVATIBLE PRODRUGS | SYNTARGA BV (NL) | 2008-10-08 | — | — | EP | claimed |
| US-7223837-B2 | Anticancer prodrugs, enhance enzymatic activation rates | SYNTARGA B.V. (NL) | 2007-05-29 | — | — | US | claimed |
| US-20060116422-A1 | Prodrugs built as multiple self-elimination-release spacers | SYNTARGA B.V. (NL) | 2006-06-01 | — | — | US | claimed |
| EP-1560599-A1 | PRODRUGS BUILT AS MULTIPLE SELF-ELIMINATION-RELEASE SPACERS | Syntarga B.V. (NL) | 2005-08-10 | — | — | EP | claimed |
| US-20040121940-A1 | Elongated and multiple spacers in activatible produgs | BYONDIS B.V. (NL) | 2004-06-24 | — | — | US | claimed |
| WO-2004043493-A1 | PRODRUGS BUILT AS MULTIPLE SELF-ELIMINATION-RELEASE SPACERS | SYNTARGA B.V. (NL) | 2004-05-27 | — | — | WO | claimed |
| EP-1370298-A1 | ELONGATED AND MULTIPLE SPACERS IN ACTIVATIBLE PRODRUGS | Syntarga B.V. (NL) | 2003-12-17 | — | — | EP | claimed |
| WO-2002083180-A1 | ELONGATED AND MULTIPLE SPACERS IN ACTIVATIBLE PRODRUGS | SYNTARGA B.V. (NL) | 2002-10-24 | — | — | WO | claimed |
| EP-0961619-A4 | HYDROLYZABLE PRODRUGS FOR DELIVERY OF ANTICANCER DRUGS TO METASTATIC CELLS | BRISTOL MYERS SQUIBB CO (US) | 2001-09-26 | — | — | EP | claimed |
| EP-0961619-A1 | HYDROLYZABLE PRODRUGS FOR DELIVERY OF ANTICANCER DRUGS TO METASTATIC CELLS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-12-08 | — | — | EP | claimed |
| WO-1998013059-A1 | HYDROLYZABLE PRODRUGS FOR DELIVERY OF ANTICANCER DRUGS TO METASTATIC CELLS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-04-02 | — | — | WO | claimed |
| CN-117003791-A | Diphenylphosphinoyloxy bisphenol A compound and application thereof in preparation of whitening nonapeptide-1 | 西北工业大学 | 2023-11-07 | — | — | CN | disclosed |
| US-7705045-B2 | compounds comprising a specifier linked to two or more of the same or different leaving groups via a self-eliminating multiple release spacer or spacer system, which compounds upon a single activation step, in particular removal or transformation of the specifier, release two or more leaving groups | SYNTARGA, B.V. (NL) | 2010-04-27 | — | — | US | disclosed |
| US-20060116422-A1 | Prodrugs built as multiple self-elimination-release spacers | SYNTARGA B.V. (NL) | 2006-06-01 | — | — | US | disclosed |
| EP-1560599-A1 | PRODRUGS BUILT AS MULTIPLE SELF-ELIMINATION-RELEASE SPACERS | Syntarga B.V. (NL) | 2005-08-10 | — | — | EP | disclosed |
| WO-2004043493-A1 | PRODRUGS BUILT AS MULTIPLE SELF-ELIMINATION-RELEASE SPACERS | SYNTARGA B.V. (NL) | 2004-05-27 | — | — | WO | disclosed |
| EP-0961619-A4 | HYDROLYZABLE PRODRUGS FOR DELIVERY OF ANTICANCER DRUGS TO METASTATIC CELLS | BRISTOL MYERS SQUIBB CO (US) | 2001-09-26 | — | — | EP | disclosed |
| EP-0961619-A1 | HYDROLYZABLE PRODRUGS FOR DELIVERY OF ANTICANCER DRUGS TO METASTATIC CELLS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-12-08 | — | — | EP | disclosed |
| WO-1998013059-A1 | HYDROLYZABLE PRODRUGS FOR DELIVERY OF ANTICANCER DRUGS TO METASTATIC CELLS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116422-A1 | Prodrugs built as multiple self-elimination-release spacers | DNPEP, GUSB, APEH | CTSS 27/4885CTSK 216/4885CTSB 72/4885 |
| US-20040121940-A1 | Elongated and multiple spacers in activatible produgs | PLG, KLK1, PKM | CTSS 76/4885CTSK 91/4885CTSB 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.